-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Big Cypress Acquisition (OTCMKTS:BCYP) Vs. Orchard Therapeutics (NASDAQ:ORTX) Head-To-Head Contrast
Big Cypress Acquisition (OTCMKTS:BCYP) Vs. Orchard Therapeutics (NASDAQ:ORTX) Head-To-Head Contrast
Big Cypress Acquisition (OTCMKTS:BCYP – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Big Cypress Acquisition and Orchard Therapeutics' net margins, return on equity and return on assets.
Get Big Cypress Acquisition alerts:| Net Margins | Return on Equity | Return on Assets | |
| Big Cypress Acquisition | N/A | N/A | N/A |
| Orchard Therapeutics | -1,452.46% | -86.92% | -54.69% |
Valuation & Earnings
This table compares Big Cypress Acquisition and Orchard Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Big Cypress Acquisition | N/A | N/A | -$10,000.00 | N/A | N/A |
| Orchard Therapeutics | $1.67 million | 45.67 | -$144.58 million | ($1.33) | -0.45 |
Institutional & Insider Ownership
60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 56.5% of Orchard Therapeutics shares are owned by institutional investors. 3.3% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations for Big Cypress Acquisition and Orchard Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Big Cypress Acquisition | 0 | 0 | 2 | 0 | 3.00 |
| Orchard Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
Big Cypress Acquisition currently has a consensus price target of $17.25, indicating a potential upside of 104.38%. Orchard Therapeutics has a consensus price target of $7.75, indicating a potential upside of 1,185.03%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than Big Cypress Acquisition.
Summary
Big Cypress Acquisition beats Orchard Therapeutics on 6 of the 10 factors compared between the two stocks.
About Big Cypress Acquisition
(Get Rating)
Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.
About Orchard Therapeutics
(Get Rating)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Big Cypress Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Big Cypress Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Big Cypress Acquisition (OTCMKTS:BCYP – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
大柏收購(OTCMKTS：BCYP-GET Rating)和果園治療(納斯達克：ORTX-GET Rating)都是小盤醫療公司，但哪隻是優勢股？我們將根據兩家公司的收益、估值、盈利能力、風險、分析師建議、股息和機構持股等方面的實力進行比較。
Profitability
盈利能力
This table compares Big Cypress Acquisition and Orchard Therapeutics' net margins, return on equity and return on assets.
此表比較了Big Cypress收購和Orchard Treeutics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Big Cypress Acquisition | N/A | N/A | N/A |
| Orchard Therapeutics | -1,452.46% | -86.92% | -54.69% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 大柏樹收購 | 不適用 | 不適用 | 不適用 |
| 果園治療學 | -1,452.46% | -86.92% | -54.69% |
Valuation & Earnings
估值與收益
This table compares Big Cypress Acquisition and Orchard Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Big Cypress收購和Orchard Treeutics的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Big Cypress Acquisition | N/A | N/A | -$10,000.00 | N/A | N/A |
| Orchard Therapeutics | $1.67 million | 45.67 | -$144.58 million | ($1.33) | -0.45 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 大柏樹收購 | 不適用 | 不適用 | -$10,000.00 | 不適用 | 不適用 |
| 果園治療學 | 167萬美元 | 45.67 | -1.4458億美元 | ($1.33) | -0.45 |
Institutional & Insider Ownership
機構與內部人持股
60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 56.5% of Orchard Therapeutics shares are owned by institutional investors. 3.3% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
60.2%的大柏樹收購股份由機構投資者持有。相比之下，Orchard Treeutics 56.5%的股份由機構投資者持有。Orchard Treeutics 3.3%的股份由內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一家公司有望實現長期增長。
Analyst Recommendations
分析師建議
This is a summary of current recommendations for Big Cypress Acquisition and Orchard Therapeutics, as reported by MarketBeat.
這是MarketBeat報道的對Big Cypress收購和Orchard Treeutics的當前建議的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Big Cypress Acquisition | 0 | 0 | 2 | 0 | 3.00 |
| Orchard Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 大柏樹收購 | 0 | 0 | 2 | 0 | 3.00 |
| 果園治療學 | 1 | 2 | 3 | 0 | 2.33 |
Big Cypress Acquisition currently has a consensus price target of $17.25, indicating a potential upside of 104.38%. Orchard Therapeutics has a consensus price target of $7.75, indicating a potential upside of 1,185.03%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than Big Cypress Acquisition.
大柏樹收購目前的一致目標價為17.25美元，表明潛在上行空間為104.38%。Orchard Treateutics的共識目標價為7.75美元，表明潛在漲幅為1185.03%。考慮到Orchard Treeutics的更高可能上行空間，分析師們顯然認為Orchard Treeutics比Big Cypress收購更有利。
Summary
摘要
Big Cypress Acquisition beats Orchard Therapeutics on 6 of the 10 factors compared between the two stocks.
與兩隻股票相比，大柏樹收購在10個因素中有6個擊敗了Orchard Treeutics。
About Big Cypress Acquisition
關於大柏樹的收購
(Get Rating)
(獲取評級)
Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.
大柏樹收購公司沒有重要的業務。公司擬通過合併、換股、購股、重組或類似的業務合併等方式收購資產和業務。它主要集中在生命科學領域。該公司成立於2020年，總部設在佛羅裏達州邁阿密海灘。
About Orchard Therapeutics
關於果園治療公司
(Get Rating)
(獲取評級)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Orchard Treateutics公司是一家生物製藥公司，在英國、歐盟和美國開發針對嚴重和危及生命的罕見疾病的基因療法。該公司的基因療法尋求將患者的造血幹細胞轉化為基因修飾的細胞藥物產品，通過單一給藥來治療患者的疾病。它提供Strimvelis，一種基於伽瑪逆轉錄病毒的產品，用於治療腺苷脱氨酶-嚴重聯合免疫缺陷(ADA-SCID)。該公司的臨牀開發產品包括用於治療ADA-SCID的OTL-101；用於治療異色性腦白質營養不良的OTL-200；用於治療Wiskott-Aldrich綜合徵的OTL-103；用於X連鎖慢性肉芽腫疾病的OTL-102；以及用於輸血依賴型β-地中海貧血的OTL-300。其臨牀前計劃包括針對I型粘多糖病的OTL-203、針對MPS-IIIA型的OTL-201以及針對IIIB型粘多糖病的OTL-202。它與Pharming Group N.V.就OTL-105的研究、開發、製造和商業化達成了戰略合作協議。OTL-105是一種用於治療遺傳性血管性水腫的體外自體造血幹細胞基因療法。該公司前身為Orchard Rx Limited。Orchard Treeutics plc成立於2015年，總部設在英國倫敦。
Receive News & Ratings for Big Cypress Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Big Cypress Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
接受《大柏樹收購日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Big Cypress收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧